ZA951679B - Pharmaceutical agents for the treatment of myocardial reperfusion injury and myocardial stunning - Google Patents

Pharmaceutical agents for the treatment of myocardial reperfusion injury and myocardial stunning

Info

Publication number
ZA951679B
ZA951679B ZA951679A ZA951679A ZA951679B ZA 951679 B ZA951679 B ZA 951679B ZA 951679 A ZA951679 A ZA 951679A ZA 951679 A ZA951679 A ZA 951679A ZA 951679 B ZA951679 B ZA 951679B
Authority
ZA
South Africa
Prior art keywords
myocardial
treatment
reperfusion injury
pharmaceutical agents
stunning
Prior art date
Application number
ZA951679A
Other languages
English (en)
Inventor
Elizabeth A Kitsis
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA951679B publication Critical patent/ZA951679B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ZA951679A 1994-03-02 1995-03-01 Pharmaceutical agents for the treatment of myocardial reperfusion injury and myocardial stunning ZA951679B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20484494A 1994-03-02 1994-03-02

Publications (1)

Publication Number Publication Date
ZA951679B true ZA951679B (en) 1996-09-02

Family

ID=22759686

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA951679A ZA951679B (en) 1994-03-02 1995-03-01 Pharmaceutical agents for the treatment of myocardial reperfusion injury and myocardial stunning

Country Status (11)

Country Link
EP (1) EP0679396A1 (xx)
JP (1) JPH07267859A (xx)
KR (1) KR950026521A (xx)
CN (1) CN1112919A (xx)
AU (1) AU1355095A (xx)
CA (1) CA2143544A1 (xx)
FI (1) FI950951A (xx)
HU (1) HUT71896A (xx)
IL (1) IL112747A0 (xx)
RU (1) RU95102777A (xx)
ZA (1) ZA951679B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
ES2654816T3 (es) * 2005-12-21 2018-02-15 Pharming Intellectual Property B.V. Uso del inhibidor C1 para la prevención de lesión de reperfusión de isquemia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
ES2053609T3 (es) * 1987-04-24 1994-08-01 Abbott Lab Derivados de urea inhibidores de lipoxigenasa.
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
JPH05508153A (ja) * 1990-06-12 1993-11-18 スミスクライン・ビーチャム・コーポレイション ５―リポキシゲナーゼ経路およびシクロオキシゲナーゼ経路で媒介される疾患の阻害
JPH06504779A (ja) * 1990-12-13 1994-06-02 スミスクライン・ビーチャム・コーポレイション 新規ｃｓａｉｄｓ
US5140047A (en) * 1991-05-03 1992-08-18 Smithkline Beecham Corporation Lipoxygenase inhibitors
FR2677477B1 (fr) * 1991-06-06 1993-08-20 Bellon Labor Sa Roger Nouveaux derives de l'oxazole leur preparation, leur utilisation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
JPH07267859A (ja) 1995-10-17
CN1112919A (zh) 1995-12-06
RU95102777A (ru) 1997-01-20
HU9500636D0 (en) 1995-04-28
AU1355095A (en) 1995-09-07
EP0679396A1 (en) 1995-11-02
IL112747A0 (en) 1995-05-26
FI950951A (fi) 1995-09-03
KR950026521A (ko) 1995-10-16
CA2143544A1 (en) 1995-09-03
HUT71896A (en) 1996-02-28
FI950951A0 (fi) 1995-03-01

Similar Documents

Publication Publication Date Title
GB9518115D0 (en) Triazole derivatives and their use as therapeutic agents
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
GB9701206D0 (en) Serine derivatives and their use as therapeutic agents
SG99279A1 (en) Myoblast therapy for cosmetic treatment
GB9501893D0 (en) Animal treatment apparatus
GB9515775D0 (en) Piperidine derivatives and their use as therapeutic agents
PL331465A1 (en) Novel compounds and agents for treating diseases associated with triptase activity
HUT76676A (en) Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
EP0975651A4 (en) TRANSGENIC ANIMALS AND CELL LINES FOR THE SCREENING OF MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
GB9219425D0 (en) Therapeutic agent and its use
HU9502722D0 (en) Amino-methyl-phosphonic- and amino-methyl-phosphinic-acid derivatives and their use for treating degenerative membrum diseases
GB9222260D0 (en) Skin treatment
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
HU9500636D0 (en) Pharmaceutical agents for the treatment of myocardial reperfusion injury and myocardial stunning
IL112681A0 (en) Opioid peptides for the treatment of pain and use thereof
SG47098A1 (en) Diamines in the treatment of arrhythmia
GB9317943D0 (en) Treatment of laminitis
GB9218773D0 (en) Skin treatment
GB9616504D0 (en) Therapeutic product and its use
GB9408179D0 (en) Novel opioid peptides for the treatment of pain and use thereof
LV5035A3 (lv) Preparats govju endometritu profilaksei un arstesanai
GB9317989D0 (en) Treatment of laminitis
IL104497A0 (en) Material of animal origin for use in surgery